Moxonidine in Patients Undergoing Vascular Surgery

• Status: Terminated
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Investigating the perioperative effect of moxonidine. In a randomized double-blind fashion, patients undergoing vascular surgery will receive moxonidine 0.2 mg or placebo from the day before surgery until day 4 after surgery. Holter-EKG for 48 h, starting just before surgery. Repeated 12-lead EKG, measurements of Troponin I and BNP, clinical visitations, follow-up interviews at 6 and 12 months

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Basel, Switzerland
• Treatments: Moxonidine

Criteria

Inclusion Criteria:

• abdominal aortic or peripheral vascular surgery

Exclusion Criteria:

• unstable angina,

• severe symptomatic heart failure (NYHA IV)

• systolic blood pressure at rest < 100 mmHg

• bradycardia (<50/min)

• higher grade AV heart block

• creatinine clearance < 30 ml/min

• pregnancy

• no consent